Kun-Long Hung | Personalized Medicine | Top Pharmaceutical Breakthrough Discovery Award

Published on by Top Pharmaceutical

Top Pharmaceutical Breakthrough Discovery Award

Kun-Long Hung
Fu Jen Catholic University Hospital, Taiwan

Kun-Long Hung
Affiliation Fu Jen Catholic University Hospital
Country Taiwan
Scopus ID 7202728402
Documents 81
Citations 1,862
h-index 23
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Kun-Long Hung is a Taiwanese clinician and researcher associated with Fu Jen Catholic University Hospital. His scholarly record demonstrates sustained contributions to personalized medicine, pediatric neurology, genetic disorders, developmental diseases, and translational healthcare research. According to Scopus metrics, his publication portfolio includes more than eighty indexed documents and a substantial citation impact within the medical research community.[1]

Abstract

This article summarizes the academic profile and scientific achievements of Kun-Long Hung. His research activities have focused on personalized medicine approaches, pediatric neurological disorders, genetic diagnostics, and evidence-based clinical practice. Through multidisciplinary collaborations, he has contributed to improved understanding of rare diseases and patient-centered healthcare strategies.[1]

Keywords

Personalized Medicine, Pediatric Neurology, Genetic Disorders, Clinical Research, Rare Diseases, Translational Medicine, Precision Healthcare, Developmental Disorders, Neurogenetics, Medical Innovation.

Introduction

The advancement of personalized medicine depends on researchers who integrate clinical observations with scientific investigation. Kun-Long Hung has participated in studies addressing neurological and genetic conditions affecting children and families. His published work reflects an ongoing commitment to improving diagnostic accuracy and therapeutic decision-making in modern healthcare environments.[2]

Research Profile

Based in Taiwan, Hung has established a recognized publication record supported by 81 indexed documents, 1,862 citations, and an h-index of 23. His research portfolio spans neurodevelopmental disorders, pediatric epilepsy, genetic syndromes, and precision medicine applications. These metrics indicate consistent scholarly engagement and meaningful influence across multiple areas of clinical medicine.[1]

Research Contributions

Hung has contributed to investigations involving developmental delay, neurofibromatosis, Dravet syndrome, tubulinopathy, and other neurological disorders. His work frequently combines genetic evaluation with clinical assessment to support individualized treatment planning. Such contributions align closely with contemporary precision medicine objectives and patient-focused healthcare models.[3]

Publications

Among his notable publications are studies on neurofibromatosis management in Taiwan, neurological manifestations of SARS-CoV-2 infection in children, developmental delay diagnostics, and rare genetic disorders. These publications demonstrate continued participation in clinically relevant research that addresses both local and international healthcare challenges while supporting evidence-based practice.[2]

Research Impact

The citation performance associated with Hung’s publications reflects engagement from researchers across medical and scientific disciplines. His studies have contributed to discussions involving diagnosis, disease management, and long-term outcomes in pediatric populations. This influence supports continued visibility within international biomedical literature and healthcare research communities.[1]

Award Suitability

The International Top Pharmaceutical Awards recognize researchers whose work advances healthcare innovation and scientific understanding. Hung’s contributions to personalized medicine, combined with his publication record and citation impact, align with the objectives of recognizing meaningful research achievements. His work illustrates the integration of clinical expertise and translational investigation.[4]

Conclusion

Kun-Long Hung has developed a substantial academic profile through research focused on pediatric neurology, genetic medicine, and individualized healthcare. His scientific contributions, publication metrics, and collaborative activities demonstrate continued involvement in advancing medical knowledge. These achievements provide a strong foundation for recognition within international research and healthcare award programs.

References

  1. Elsevier. (n.d.). Scopus Author Profile: Hung, K. L. (Author ID: 7202728402). Scopus. https://www.scopus.com/authid/detail.uri?authorId=7202728402
  2. Chu, Y. J., Wong, L. C., Ho, C. S., Lee, W. T., & Hung, K. L. (2024). Neurological manifestations of SARS-CoV-2 infection in children in Taiwan: A cross-sectional multicenter study. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2024.01.001
  3. Huang, C. S., Hung, P. L., Fan, P. C., Lee, W. T., & Hung, K. L. (2021). Clinical spectrum and comorbidities of Dravet syndrome in Taiwan and possible molecular mechanisms. Scientific Reports, 11, Article 15092. https://pubmed.ncbi.nlm.nih.gov/34642351/
  4. Hung, K. L., Lu, J. F., Su, D., Hsu, S., & Wong, L. C. (2022). Tubulinopathy presenting as developmental and epileptic encephalopathy. Children, 9(11), 1663. https://doi.org/10.3390/children9111663
  5. Liang, J. S., Hung, K. L., Lin, L., Keng, W. T., & Lu, J. F. (2023). Novel PEX1 mutations in fibroblasts from children with Zellweger spectrum disorders exhibit temperature-sensitive characteristics. Epilepsy & Behavior, 147, 109387. https://doi.org/10.1016/j.yebeh.2023.109387

Olfa Trabelsi | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Olfa Trabelsi
University of Technology of Compiègne, France

Olfa Trabelsi
Affiliation University of Technology of Compiègne
Country France
Scopus ID 36025990200
Documents 29
Citations 685
h-index 13
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards
ORCID 0000-0003-4415-8478

Olfa Trabelsi is a researcher affiliated with the University of Technology of Compiègne in France and is recognized for interdisciplinary research activities within biomedical engineering and personalized medicine. Her academic work combines computational mechanics with biological applications and demonstrates integration between engineering concepts and medical analysis. Bibliometric indicators and publication records indicate continuing contributions in tissue engineering and patient-specific modeling studies.[1]

Abstract

This article summarizes the academic profile and scientific contributions associated with Olfa Trabelsi. Research activities mainly involve computational biomechanics, tissue engineering applications, and biomedical modeling methodologies. Scientific outputs further indicate interdisciplinary collaborations designed to improve analytical approaches used in personalized medical systems and healthcare technologies.[2]

Keywords

Personalized Medicine, Biomedical Engineering, Biomechanics, Tissue Engineering, Computational Modeling, Medical Simulation, Patient-Specific Analysis.

Introduction

Current advances in healthcare increasingly rely on computational and patient-centered methodologies for diagnostic and therapeutic improvements. Olfa Trabelsi has participated in research environments involving biomedical analysis and engineering applications designed for clinical relevance. Such studies contribute toward the understanding of tissue behavior and individualized medical systems.[3]

Research Profile

According to ORCID records, Olfa Trabelsi currently serves as an Associate Professor at the University of Technology of Compiègne and has academic experience in biomechanics and computational mechanics research. Educational activities include doctoral studies in computational mechanics and multidisciplinary biomedical applications.[4]

Research Contributions

Research contributions include computational analysis of biological tissues, mechanical characterization studies, and predictive modeling techniques. Published investigations have focused on tracheal systems, vascular biomechanics, tissue remodeling processes, and personalized therapeutic assessment methods.[5]

Publications

Publication records demonstrate collaborative research across multiple biomedical disciplines and engineering frameworks. Scientific articles include computational bone remodeling studies, tissue engineering analysis, aneurysm prediction models, and tracheal mechanical simulations. Published works further illustrate integration between clinical requirements and engineering methodologies within patient-specific biomedical systems.

Research Impact

Citation statistics indicate measurable influence across scientific communities and interdisciplinary domains. The available bibliometric indicators suggest continuing relevance of published work and recognition through citations, collaborative outputs, and international dissemination activities.

Award Suitability

Academic metrics and scientific activities suggest alignment with criteria commonly associated with international research recognition programs. Contributions involving personalized medicine and biomedical technologies support consideration within broader scientific achievement categories.

Conclusion

Olfa Trabelsi represents an academic profile characterized by multidisciplinary investigation and continuing scientific activity. Research outputs demonstrate integration of engineering principles with healthcare technologies and support continuing development of personalized biomedical systems.

References

  1. Trabelsi, O., Duprey, A., Favre, J.P., & Avril, S. (2016). Predictive models with patient specific material properties for the biomechanical behavior of ascending thoracic aneurysms. Annals of Biomedical Engineering.
    https://doi.org/10.1007/s10439-015-1374-8
  2. Trabelsi, O., Davis, F.M., Rodriguez-Matas, J.F., Duprey, A., & Avril, S. (2015). Patient specific stress and rupture analysis of ascending thoracic aneurysms. Journal of Biomechanics.
    https://doi.org/10.1016/j.jbiomech.2015.04.035
  3. Trabelsi, O., et al. (2022). A simple and effective 1D-element discrete-based method for computational bone remodeling. Computer Methods in Biomechanics and Biomedical Engineering.
    https://doi.org/10.1080/10255842.2021.1943370
  4. Trabelsi, O., et al. (2020). In vitro histomechanical effects of enzymatic degradation in carotid arteries during inflation tests with pulsatile loading. Journal of Mechanical Behavior of Biomedical Materials.
    https://doi.org/10.1016/j.jmbbm.2019.103550
  5. Ruben, R.B., Carvalho, M., & Trabelsi, O. (2026). Biomechanics Analysis in Tissue Engineering. Bioengineering.
    https://doi.org/10.3390/bioengineering13060703

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., … Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., … Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023